SAA’s Helpful Hints: Community Wisdom – Perspectives Gained Through Battling Spondyloarthritis

SAA’s Helpful Hints: Community Wisdom – Perspectives Gained Through Battling Spondyloarthritis

By Spondylitis Association of America

Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. Living with spondyloarthritis can be difficult and challenging at times, however, throughout the process we can learn a lot about ourselves, our surroundings, and life in general. In this installment, we asked our online community, “If you have learned anything special about life or human nature as a result of spondyloarthritis, what is it?”

Combination Therapy of TNF Inhibitors and NSAIDs May Help Slow Down Radiographic Progression in Ankylosing Spondylitis

Combination Therapy of TNF Inhibitors and NSAIDs May Help Slow Down Radiographic Progression in Ankylosing Spondylitis

By Spondylitis Association of America

According to findings from a recent cohort study, the combined use of nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor (TNF) inhibitors, may help slow the progression of damage to the spine in ankylosing spondylitis, mitigating some of the effects of the disease.

Spondyloarthritis Medication Preferences Study

Spondyloarthritis Medication Preferences Study

By Spondylitis Association of America

Researchers at Boston University are conducting a survey to help learn about how people with ankylosing spondylitis and related conditions choose medications. The survey will take 15-20 minutes to complete. Those who finish the survey may win one of five $50 gift cards.

SAA’s Helpful Hints: Community Wisdom – Practicing Self- Care

SAA’s Helpful Hints: Community Wisdom – Practicing Self- Care

By Spondylitis Association of America

Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. In this installment, we asked our online community, “Do you practice self-care? What do you do to treat yourself?"

Breaking News: FDA Approves Certolizumab Pegol, (CIMZIA®) For Non-Radiographic Axial Spondyloarthritis, Making It The First Biologic Available To Those Living With Nr-axSpA.

Breaking News: FDA Approves Certolizumab Pegol, (CIMZIA®) For Non-Radiographic Axial Spondyloarthritis, Making It The First Biologic Available To Those Living With Nr-axSpA.

By Spondylitis Association of America

On March 28, 2019, the U.S. FDA announced the approval of the TNF inhibitor, certolizumab pegol (CIMZIA®) for the treatment for non-radiographic axial spondyloarthritis (nr-axSpA.) This is the first, and currently only biologic agent to gain approval for nr-axSpA in the U.S., providing those living with the condition access to a new class of medication.

RSS
12345678910Last

Stay Informed

Text/HTML

Careers

Visit our careers page for available positions

Contact Us

Spondylitis Association of America

16360 Roscoe Blvd.  Ste. 100
Van Nuys, CA 91406

Email

info@spondylitis.org

Information Requests

(800) 777-8189 U.S. only
or (818) 892-1616
*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.

Give With Confidence

Independent Charities of America